JW THERAP-B News

Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair

Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.

中信證券研究May 7 11:13

Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1

In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.

cls.cnMay 5 22:26

藥明巨諾-B：2023年度報告

Futu NewsApr 26 06:21 · Announcements

Big benefits have arrived! Pharmacovigilance is getting stronger. What's the situation?

Yao Ming Kangde's deep participation in the US healthcare field has far surpassed congressional discussions. Some senior members of the country's biotech industry have clearly opposed the bill.

券商中國Apr 17 16:06

Pharmaceutical Junuo (02126.HK): Significant results in cost reduction and efficiency explore clinical applications of self-exemption

The 2023 results are in line with our expectations. The company announced the 2023 results: revenue of 174 million yuan, up 19.3% year on year; net profit to mother - 768 million yuan. The 2023 results are in line with our expectations. Development trend Benuo

中金公司Mar 22 18:51

JW (Cayman) Therapeutics Shrinks Loss in Fiscal 2023

JW (Cayman) Therapeutics (HKG:2126) recorded a narrower attributable loss for the year ended Dec. 31, 2023, of 768 million yuan from 846.1 million yuan during the year-ago period, a Tuesday filing on

MT NewswiresMar 20 20:44

Pharmaceutical Juno-B (02126) released annual results, gross profit of 882.19 million yuan, a year-on-year increase of 50.14%

Pharmaceutical Juno-B (02126) announced its annual results for the year ended December 31, 2023. The group...

Zhitong FinanceMar 20 16:44

JW THERAP-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023 AND CHANGE IN USE OF NET PROCEEDS FROM LISTING

Futu NewsMar 20 16:34 · Announcements

The US BIO organization announced the exclusion of Medicinal Kangde membership. The reason behind this is a piece of legislation

Last week, the US Senate Homeland Security Committee passed the Biosafety Act, which prohibits federal agencies from signing contracts with foreign biotechnology companies, including Pharmacovigilus, on national security grounds.

cls.cnMar 14 14:08

A major favorable raid, and the 1.6 trillion innovative drug sector is booming!

The advantage suddenly “smashed” into the pharmaceutical sector!

券商中國Mar 13 21:18

Pharmaceutical Juno-B (02126.HK) held a board meeting on March 20 to consider and approve annual results

Gelonghui, March 8, 丨 Pharmaceutical Juno-B (02126.HK) announced that the company would like to hold a board meeting on March 20, 2024 (Wednesday) to (i) consider and approve the Group's audited consolidated results for the year ended 31 December 2023 and their release; (ii) the proposed final dividend (if any); and (iii) address any other matters.

Gelonghui FinanceMar 8 16:55

JW THERAP-B: NOTICE OF BOARD MEETING

Futu NewsMar 8 16:45 · Announcements

The US Senate version of the Biosafety Act was passed at a hearing last night. What is the situation, and how should the Pharmacovigilance Department respond?

The industry believes that the bill may be fiercely discussed and repeatedly revised in the Senate and House of Representatives, and that relevant companies should “think from the bottom line.”

cls.cnMar 7 09:24

Express News | US Senate version of “Biosafety Act” passed hearing House bill hearing will be held soon

BreakingsMar 7 07:37

Express News | The U.S. Senate will hold a hearing on Wednesday to discuss the Biosafety Act proposal (S.3558)

BreakingsMar 4 14:33

A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day

Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.

Futu NewsFeb 21 16:21

Yao Ming, Kang De, made it clear again! US politicians are pressing for sanctions and investigations against the drug system. Can stock prices be desensitized under “repeated pull”?

Judging from the recent series of actions by US lawmakers against the drug class, industry experts believe that the topic of medicine may have been used as a political “tool” by relevant lawmakers, and related news may not stop after that.

cls.cnFeb 19 09:12

Express News | The number of members who co-sponsored the US Senate version of the Life Safety Act was reduced from 6 to 0

BreakingsFeb 7 14:04

Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%

Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.

Futu NewsFeb 7 10:13

Express News | Foreign media: US Senate postpones review of the biotechnology-related Chinese enterprise bill

BreakingsFeb 4 14:18